Inhibiting the cholesterol biosynthesis pathway with statins during this IFN-γ+ to IL-10+ switching process has been found to create a block in immune resolution, resulting in a substantial decrease in IL-10 production [30], which is implicated in the pathogenesis of SLE. The gene discussed is IL10; the disease is systemic lupus erythematosus.